Publications by authors named "T G Waddell"
Article Synopsis
- The family of PEComa consists of various mesenchymal tumors with myomelanocytic characteristics, including a unique type linked to TFE3 gene rearrangement.
- Recent findings show that the YAP1::TFE3 fusion is present in clear cell stromal tumors of the lung and certain inflammatory spindle cell PEComas, though the connection between these two remains uncertain.
- This report details a case of pulmonary malignant PEComa with TFE3 rearrangement that also has the YAP1::TFE3 fusion, contributing to the understanding of the characteristics and genetic factors of lung neoplasms related to PEComa.
Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.
Objectives: This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.
Purpose Of Review: In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a treatment option supported by emerging long-term efficacy data including overall survival and quality of life. We specifically focus on tivozanib, a potent and selective inhibitor of vascular endothelial growth factor receptor, which has comparable efficacy to other single-agent TKIs in frontline treatment for mRCC while exhibiting fewer off-target side effects.
Recent Findings: Combination therapy with TKIs and checkpoint inhibitors (CPIs) and CPI/CPI combination therapies, as well as TKI monotherapy are recommended frontline treatment options for mRCC.
Article Synopsis
- The study investigated the feasibility and safety of active surveillance for patients with multiple ground glass opacities (GGOs) in the lungs, which are a common concern in medical imaging.
- A total of 337 patients, primarily older adults with a significant history of smoking, were enrolled and monitored over time, with each GGO documented via CT scans every 6 to 12 months.
- Preliminary findings suggest that active surveillance is a viable management option for patients, with ongoing assessments planned to evaluate long-term safety and outcomes over five years.